CASI Pharmaceuticals (CASIF) Operating Income (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Operating Income came in at -$77.2 million in Q4 2025, down 497.75% YoY from $19.4 million in Q4 2024, and down 622.98% on a QoQ basis from -$10.7 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Operating Income (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Operating Income data on file, last reported at -$77.2 million in Q4 2025.
- Quarterly Operating Income fell 497.75% year-over-year to -$77.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$109.4 million (down 176.05% YoY) and the FY2025 annual result came in at -$45.0 million, down 13.59% from the prior year.
- Operating Income fell to -$77.2 million in Q4 2025, from -$10.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$3.4 million in Q4 2023 to a low of -$77.2 million in Q4 2025.
- A 4-year average of -$13.0 million and a median of -$9.1 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 77.1% — and 2025, when it plunged 497.75%.
- Tracing CASIF's Operating Income over 4 years: stood at -$15.0 million in 2022, then soared by 77.1% to -$3.4 million in 2023, then plunged by 276.83% to -$12.9 million in 2024, then sank by 497.75% to -$77.2 million in 2025.
- The last three Operating Income figures came in at -$77.2 million (Q4 2025), -$10.7 million (Q3 2025), and -$11.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.19 Mn |
| Sep 30, 2025 | -10.68 Mn |
| Jun 30, 2025 | -11.13 Mn |
| Mar 31, 2025 | -10.38 Mn |
| Dec 31, 2024 | -12.91 Mn |
| Sep 30, 2024 | -8.46 Mn |
| Jun 30, 2024 | -8.79 Mn |
| Mar 31, 2024 | -9.45 Mn |
| Dec 31, 2023 | -3.43 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -9.35 Mn |
| Mar 31, 2023 | -7.21 Mn |
| Dec 31, 2022 | -14.97 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.96 Mn |